慢性疹的成本效益高的奥马利祖马布剂量:系统性审查和网络元分析
Amin Tajerian1, Ali Pourvali2, Maryam Khoshkhui3
1School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Archives of dermatological research
|December 14, 2024
概括
在资源有限的环境中,300毫克的奥马利祖马布剂量是治疗慢性疹最有效的. 较低的剂量 (75毫克) 不推用于抗组胺耐药病例,建议使用更高的剂量以获得更好的结果.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药物经济学 药物经济学
背景情况:
- 慢性疹 (CU) 显著影响生活质量,需要长期管理.
- 像奥马利祖马布这样昂贵的治疗方法在低收入国家存在挑战.
- 对成本效益高的奥马利祖马布剂量的研究对于管理CU至关重要.
研究的目的:
- 为了确定奥马利祖马布治疗慢性疹的最具成本效益的剂量.
- 评估对抗胰岛素耐药慢性自发性疹症 (CSU) 患者的奥马利祖马布疗效.
主要方法:
- 在PubMed,MEDLINE和科学网络中对RCT (2010-2023) 的系统文献搜索.
- 使用贝叶斯随机效应模型进行网络元分析 (NMA).
- 偏差风险评估 (科克兰工具2) 和GRADE确定性评估.
主要成果:
- 与安慰剂和较低剂量相比,300毫克的奥马利祖马布剂量在降低疹活动 (UAS7,WWS,WIS) 中表现出更高的疗效.
- 在300毫克剂量下观察到更高的响应率.
- 150毫克和300毫克的剂量显示出明显更大的效果大小比75毫克和安慰剂.
结论:
- 低剂量奥马利祖马布 (75毫克) 不推用于抗组胺抗性CSU.
- 建议在6个月内以300毫克剂量开始治疗,或者从150毫克开始,并增加剂量.
- 这些剂量建议考虑了在资源有限的环境中改善慢性病管理的经济因素.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236
01:19Antiasthma Drugs: Leukotriene Modifiers
241
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
241
01:17Drugs Used in Lower Respiratory Disorders: Overview
349
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
349